The Food and Drug Administration (FDA) has approved Tyvaso DPI™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension ...
Researchers in the United Kingdom compared the potential impact on carbon footprint and asthma symptom control of switching maintenance therapy to a dry powder inhaler vs continuing with a metered ...
Tyvaso DPI is an investigational drug-device combination therapy consisting of a dry powder formulation of treprostinil. The Food and Drug Administration (FDA) has accepted for Priority Review the New ...
Please provide your email address to receive an email when new articles are posted on . The dry powder formulation of treprostinil studied in BREEZE is in development with a reusable breath-powered ...
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Pharma, a global leader in drug delivery and active material science solutions and services, today announced that it has entered into an exclusive ...
The divided solid materials have a significant share in the products produced or employed in the pharmaceutical industries (such as active pharmaceutical ingredient (API), excipients, additives, and ...
Please provide your email address to receive an email when new articles are posted on . “Many health care systems are discussing a transition to dry-powder inhalers that have a lower carbon footprint ...
ST. PAUL, Minn.--(BUSINESS WIRE)--Kindeva Drug Delivery L.P. (Kindeva) and Cambridge Healthcare Innovations Limited (CHI) have entered into a collaboration to develop and commercialize CHI’s αeolus ...
Switching asthma patients from a pressurised metered dose inhaler (pMDI) to a dry powder inhaler (DPI) for maintenance therapy more than halves their carbon footprint without loss of asthma control, ...
Dry Powder Inhalers (DPIs) are employed to supply a safe dose of Active Pharmaceutical Ingredient (API) to the deep lung. Image Credit: Freeman Technology An excipient transports the delicate ...
SAN DIEGO, CA--(Marketwired - Aug 6, 2013) - Adamis Pharmaceuticals Corporation (OTCQB: ADMP) announced today that it has entered into an agreement to exclusively license and, with additional payment, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results